Vertex Pharmaceuticals reports $2.99 billion revenue for quarter ended March 31, 2026, up 7.8%
Vertex Pharmaceuticals reported revenue of $2.99 billion for the quarter ended March 31, 2026, an increase of 7.8% from the same quarter a year earlier ($2.77 billion).
For the same period it posted net income of $1.03 billion, up 59.6%, or $4.02 per diluted share (2.49 a year earlier).
That is a net margin of 34.5%.
On Sanad's AAOIFI Standard 21 screen, Vertex Pharmaceuticals is currently compliant: interest-bearing debt is 3.3% of market capitalisation (limit 30%), and impure income is 4.1% of revenue (limit 5%).
Is Vertex Pharmaceuticals halal?
See the full AAOIFI screening of Vertex Pharmaceuticals
See the full AAOIFI screening of Vertex Pharmaceuticals
Source: 10-Q filed with the U.S. Securities and Exchange Commission on May 5, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.